Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice

被引：6

作者：

Hotta, Katsuyuki ^{[1
,2
]}

Ninomiya, Kiichiro ^{[1
]}

Ichihara, Eiki ^{[1
]}

Kiura, Katsuyuki ^{[1
]}

机构：

[1] Okayama Univ Hosp, Dept Resp Med, Okayama, Japan

[2] Okayama Univ Hosp, Ctr Innovat Clin Med, 2-5-1 Shikata Cho, Okayama 7008558, Japan

来源：

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 24卷 / 01期

基金：

日本学术振兴会;

关键词：

Lung cancer; Treatment; Re-biopsy; CISPLATIN-BASED CHEMOTHERAPY; LOW-VOLUME HYDRATION; SPATIOTEMPORAL T790M HETEROGENEITY; EGFR-MUTANT; PROSPECTIVE FEASIBILITY; OPEN-LABEL; EXPRESSION; MUTATIONS; ALECTINIB; 1ST-LINE;

D O I：

10.1007/s10147-018-1344-x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The significance of evaluating oncogenes, including EGFR mutations, ALK abnormalities, and PD-L1 expression has become broadly recognized with recent advances in molecular biology. It is now extremely important to investigate tumor oncogene status in each patient at the initial diagnosis. By contrast, the significance of conducting a re-biopsy in the salvage setting has not been systematically reviewed. Thisreview reports that the significance of a re-biopsy varies depending on the clinical situation.

引用

页码：41 / 45

页数：5

共 37 条

[1]

[Anonymous], 2018 AACR ANN M 2018

[2]

[Anonymous], J THORAC ONCOL

[3]

[Anonymous], CLIN EFFICACY ATEZOL

[4] Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer [J].

Gainor, Justin F. ;

Dardaei, Leila ;

Yoda, Satoshi ;

Friboulet, Luc ;

Leshchiner, Ignaty ;

Katayama, Ryohei ;

Dagogo-Jack, Ibiayi ;

Gadgeel, Shirish ;

Schultz, Katherine ;

Singh, Manrose ;

Chin, Emily ;

Parks, Melissa ;

Lee, Dana ;

DiCecca, Richard H. ;

Lockerman, Elizabeth ;

Huynh, Tiffany ;

Logan, Jennifer ;

Ritterhouse, Lauren L. ;

Le, Long P. ;

Muniappan, Ashok ;

Digumarthy, Subba ;

Channick, Colleen ;

Keyes, Colleen ;

Getz, Gad ;

Dias-Santagata, Dora ;

Heist, Rebecca S. ;

Lennerz, Jochen ;

Sequist, Lecia V. ;

Benes, Cyril H. ;

Iafrate, A. John ;

Mino-Kenudson, Mari ;

Engelman, Jeffrey A. ;

Shaw, Alice T. .

CANCER DISCOVERY, 2016, 6 (10) :1118-1133

[5] EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis [J].

Gainor, Justin F. ;

Shaw, Alice T. ;

Sequist, Lecia V. ;

Fu, Xiujun ;

Azzoli, Christopher G. ;

Piotrowska, Zofia ;

Huynh, Tiffany G. ;

Zhao, Ling ;

Fulton, Linnea ;

Schultz, Katherine R. ;

Howe, Emily ;

Farago, Anna F. ;

Sullivan, Ryan J. ;

Stone, James R. ;

Digumarthy, Subba ;

Moran, Teresa ;

Hata, Aaron N. ;

Yagi, Yukako ;

Yeap, Beow Y. ;

Engelman, Jeffrey A. ;

Mino-Kenudson, Mari .

CLINICAL CANCER RESEARCH, 2016, 22 (18) :4585-4593

[6] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer [J].

Gandhi, L. ;

Rodriguez-Abreu, D. ;

Gadgeel, S. ;

Esteban, E. ;

Felip, E. ;

De Angelis, F. ;

Domine, M. ;

Clingan, P. ;

Hochmair, M. J. ;

Powell, S. F. ;

Cheng, S. Y. -S. ;

Bischoff, H. G. ;

Peled, N. ;

Grossi, F. ;

Jennens, R. R. ;

Reck, M. ;

Hui, R. ;

Garon, E. B. ;

Boyer, M. ;

Rubio-Viqueira, B. ;

Novello, S. ;

Kurata, T. ;

Gray, J. E. ;

Vida, J. ;

Wei, Z. ;

Yang, J. ;

Raftopoulos, H. ;

Pietanza, M. C. ;

Garassino, M. C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2078-2092

[7] Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment [J].

Haratani, K. ;

Hayashi, H. ;

Tanaka, T. ;

Kaneda, H. ;

Togashi, Y. ;

Sakai, K. ;

Hayashi, K. ;

Tomida, S. ;

Chiba, Y. ;

Yonesaka, K. ;

Nonagase, Y. ;

Takahama, T. ;

Tanizaki, J. ;

Tanaka, K. ;

Yoshida, T. ;

Tanimura, K. ;

Takeda, M. ;

Yoshioka, H. ;

Ishida, T. ;

Mitsudomi, T. ;

Nishio, K. ;

Nakagawa, K. .

ANNALS OF ONCOLOGY, 2017, 28 (07) :1532-1539

[8] Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non-Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI [J].

Hata, Akito ;

Katakami, Nobuyuki ;

Yoshioka, Hiroshige ;

Kaji, Reiko ;

Masago, Katsuhiro ;

Fujita, Shiro ;

Imai, Yukihiro ;

Nishiyama, Akihiro ;

Ishida, Tadashi ;

Nishimura, Yoshihiro ;

Yatabe, Yasushi .

JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (11) :1553-1559

[9] Spatiotemporal T790M Heterogeneity in a Patient with EGFR-Mutant Non-Small-Cell Lung Cancer [J].

Hata, Akito ;

Masago, Katsuhiro ;

Katakami, Nobuyuki ;

Imai, Yukihiro ;

Yatabe, Yasushi .

JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (08) :E64-E65

[10] Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial [J].

Herbst, Roy S. ;

Baas, Paul ;

Kim, Dong-Wan ;

Felip, Enriqueta ;

Perez-Gracia, Jose L. ;

Han, Ji-Youn ;

Molina, Julian ;

Kim, Joo-Hang ;

Arvis, Catherine Dubos ;

Ahn, Myung-Ju ;

Majem, Margarita ;

Fidler, Mary J. ;

de Castro, Gilberto, Jr. ;

Garrido, Marcelo ;

Lubiniecki, Gregory M. ;

Shentu, Yue ;

Im, Ellie ;

Dolled-Filhart, Marisa ;

Garon, Edward B. .

LANCET, 2016, 387 (10027) :1540-1550

← 1 2 3 4 →